Recent studies suggested predictive biomarkers for ICI response based on tumour intrinsic genomic variants and TME phenotypes, for example, positive correlations of tumour mutation burdens, PD‐1/PD‐L1 expression and T cell infiltration with ICI efficacy in NSCLC patients.4, 5, 6, 7. The gene discussed is CD274; the disease is neoplasm.